<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394575</url>
  </required_header>
  <id_info>
    <org_study_id>BR-RT-001</org_study_id>
    <nct_id>NCT01394575</nct_id>
  </id_info>
  <brief_title>Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients</brief_title>
  <acronym>IMRT-SIB</acronym>
  <official_title>Phase 2 Study of Whole Breast Irradiation With Inversely Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study. In patients with node-negative invasive breast cancer or carcinoma&#xD;
      in situ treated by breast conserving surgery, postoperative whole breast irradiation with&#xD;
      inversely intensity modulated radiotherapy and a simultaneous integrated boost is technically&#xD;
      feasible. The aim of this study is to evaluate the radiation toxicity, cosmetic outcome and&#xD;
      local control rate in a single center&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation toxicity</measure>
    <time_frame>first analysis will occur 2 year after accrual of all patients</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>first analysis will occur 2 year after accrual of all patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ipsilateral breast recurrence</measure>
    <time_frame>first analysis will occur 5 year after accrual of all patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>first analysis will occur 5 year after accrual of all patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>first analysis will occur 5 year after accrual of all patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>first analysis will occur 5 year after accrual of all patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT-SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT with an simultaneous integrated boost</intervention_name>
    <description>IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed</description>
    <arm_group_label>IMRT-SIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance score﹤2&#xD;
&#xD;
          -  All patients aged &gt;18 years and &lt; 70 years after breast conserving surgery.&#xD;
&#xD;
          -  On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the&#xD;
             breast.&#xD;
&#xD;
          -  Negative nodal status determined by sentinel node biopsy, or axillary dissection.&#xD;
             Axillary staging is not required for patients with DCIS&#xD;
&#xD;
          -  No evidence of distant metastasis&#xD;
&#xD;
          -  Gross disease may be unifocal or multifocal with pathologic (invasive and/or DCIS)&#xD;
             tumor size excised with negative margins（&gt;2mm）&#xD;
&#xD;
          -  Surgical treatment of the breast must have been lumpectomy. Re-excision of surgical&#xD;
             margins is permitted.&#xD;
&#xD;
          -  The patient must consent to be in the study and must have signed an approved consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance score≧2&#xD;
&#xD;
          -  Presence of extensive intraductal component (ductal carcinoma in situ occupying &gt; 25%&#xD;
             of the primary invasive tumour and present adjacent to the primary tumour).Suspicious&#xD;
             microcalcifications, densities, or palpable abnormalities (in the ipsilateral or&#xD;
             contralateral breast) unless biopsied and found to be benign.&#xD;
&#xD;
          -  Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant of&#xD;
             separated.&#xD;
&#xD;
          -  Metastatic disease (M1)&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  Surgical margins that cannot be microscopically assessed or are positive at pathologic&#xD;
             evaluation.&#xD;
&#xD;
          -  Psychiatric or addictive disorders that preclude obtaining informed consent or&#xD;
             adherence to protocol.&#xD;
&#xD;
          -  Collagen vascular disease, specifically dermatomyositis with a CPK level above normal&#xD;
             or with an active skin rash, systemic lupus erythematosis, or scleroderma.&#xD;
&#xD;
          -  Prior breast or thoracic RT for any condition.&#xD;
&#xD;
          -  Previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in&#xD;
             situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or&#xD;
             endometrium treated five years prior to study entry.&#xD;
&#xD;
          -  Synchronous chemotherapy or target therapy is not permitted.&#xD;
&#xD;
          -  Refusal of the patients to be included in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiayi Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Radiation Oncology, Fudan University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaozhi Yang, MD</last_name>
    <phone>862164175590</phone>
    <phone_ext>6601</phone_ext>
    <email>yzzhi2006@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Department of Radiation Oncology,Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaozhi Yang, MD</last_name>
      <phone>862164175590</phone>
      <phone_ext>6601</phone_ext>
      <email>yzzhi2006@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jiayi Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <name_title>The Department of Radiation Oncology, Fudan University Cancer Hospital</name_title>
    <organization>Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>simultaneous integrated boost</keyword>
  <keyword>tumor bed</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

